Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
*Rhus coriaria* phenolic fraction is a botanical extract derived from the fruit of the sumac plant (*Rhus coriaria*), specifically enriched for its phenolic constituents. In preclinical studies, this fraction has demonstrated potent antihyperlipidemic and hepatoprotective effects, significantly improving lipid profiles by lowering total cholesterol, triglycerides, and LDL while increasing HDL levels. Its mechanism of action is attributed to its strong antioxidant and anti-inflammatory properties, which include the reduction of oxidative stress markers like malondialdehyde and the restoration of endogenous antioxidants such as glutathione. Additionally, it has been shown to mitigate liver damage by reducing elevated levels of hepatic enzymes such as alanine transaminase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rhus coriaria phenolic fraction.